The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.

Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, Yang Tian, Magdeleine Hung, Wanchi Fung, Randall W Vivian, James Trenkle, James Taylor, Kyla Bjornson, Steven Bondy, Xiaohong Liu, John Link, Johan Neyts, Roman Sakowicz, Weidong Zhong, Hengli Tang, Uli Schmitz
Format:	article
Language:	EN
Published:	Public Library of Science (PLoS) 2012
Subjects:	Medicine R Science Q
Online Access:	https://doaj.org/article/eeeef54f94cb49e4bd1ec7bb38024a99
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.

Similar Items